GET IT CHECKED!!! If the doctor pooh-poohs it, get it checked by a different doctor. Ultimately, what you do is up to you, ...

HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

A new urine-based tumor DNA (utDNA) test shows promise in predicting treatment response and recurrence risk, helping personalize bladder cancer care.

To prevent ovarian cancers, fallopian tube removal is on an upsurge — and diagnostic manuals are finally catching up.

While some of these tumors may produce hormones, the tumor in this case was non-functional and was discovered only through microscopic analysis after removal during surgery for an unrelated condition.

Promising ADC Efficacy in Resistant Ovarian Cancer: Lilly’s investigational FRα-targeting ADC, LY4170156, showed a 55% response rate at the proposed Phase II dose in platinum-resistant ovarian cancer, ...

The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and platinum-sensitive ovarian cancer.

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer—and offers a potential pathway for new treatments.

Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.

A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little ...

It found heated intraperitoneal chemotherapy helped women with ovarian cancer live longer.